SSR-126517E Uses, Dosage, Side Effects and more
SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
| Attribute | Details |
|---|---|
| Trade Name | SSR-126517E |
| Generic | SSR-126517E |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in thrombosis and venous thromboembolism.
How SSR-126517E works
SSR126517E is a biotinylated form of idraparinux. It can be neutralized with intravenous recombinant avidin. Avidin binds biotinylated fondaparinux with high affinity, and the complex is then rapidly cleared.
SSR126517E also has an advantage over idraparinux in that an antidote is available when rapid reversal is required. None of the new agents has a specific antidote except SSR126517E. The lack of an antidote in other anticoagulants agents has been a major cause for the development of SSR126517E.
